Evidence map›Paper›PMID 38543287›Full record

ArticlePharmaceutics2024

AMPK Activation by

Madeline Günther, Peter Schnierle, Thorsten Rose, Jonathan Schlegel, Georg Boonen, Jürgen Drewe, Eduardo Muñoz, Bernd L Fiebich, Carsten Culmsee

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Pilot Investigation on the Metabolic Effects ofInternational journal of molecular sciences · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Madeline GüntherInstitute of Pharmacology and Clinical Pharmacy, Biochemisch-Pharmakologisches Centrum Marburg, Philipps-University Marburg, Karl-von-Frisch-Straße 2, 35032 Marburg, Germany.
Peter SchnierleVivaCell Biotechnology GmbH, Ferdinand-Porsche-Str. 5, 79211 Denzlingen, Germany.
Thorsten RoseVivaCell Biotechnology GmbH, Ferdinand-Porsche-Str. 5, 79211 Denzlingen, Germany.
Jonathan SchlegelCenter for Mind, Brain and Behavior, 35032 Marburg, Germany.
Georg BoonenMedical Research, Max Zeller Soehne AG, 8590 Romanshorn, Switzerland.
Jürgen DreweMedical Research, Max Zeller Soehne AG, 8590 Romanshorn, Switzerland.ORCID 0000-0001-5178-7825
Eduardo MuñozVivaCell Biotechnology España SL, Parque Científico Tecnológico Rabanales 21, 14014 Córdoba, Spain.ORCID 0000-0001-8478-5842
Bernd L FiebichVivaCell Biotechnology GmbH, Ferdinand-Porsche-Str. 5, 79211 Denzlingen, Germany.
Carsten CulmseeInstitute of Pharmacology and Clinical Pharmacy, Biochemisch-Pharmakologisches Centrum Marburg, Philipps-University Marburg, Karl-von-Frisch-Straße 2, 35032 Marburg, Germany.ORCID 0000-0002-5121-5015
Max Zeller Söhne (Switzerland) · CHPhilipps University of Marburg · DEBrain (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

3T3L1 adipocytesAMPK activationC2C12 myoblastsCimicifuga racemosaHEPG2 liver cellsherbal extractHT22 neuronal cellsHTRF technologymetabolic effectsresilienceZe 450

Identifiers

PMID38543287
PMCPMC10975534
OpenAlexW4392764218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.